Temozolomide

Modify Date: 2024-01-02 09:46:28

Temozolomide Structure
Temozolomide structure
 Common Name Temozolomide
CAS Number 85622-93-1 Molecular Weight 194.151
Density 2.0±0.1 g/cm3 Boiling Point 526.6±42.0 °C at 760 mmHg
Molecular Formula C6H6N6O2 Melting Point 212°C dec.
MSDS Chinese USA Flash Point 272.3±27.9 °C
Symbol GHS07 GHS08
GHS07, GHS08		 Signal Word Danger

 Use of Temozolomide


Temozolomide (NSC 362856; CCRG 81045) is an oral DNA alkylating agent used to treat some brain cancers.

 Names

Name temozolomide
Synonym More Synonyms

 Temozolomide Biological Activity

Description Temozolomide (NSC 362856; CCRG 81045) is an oral DNA alkylating agent used to treat some brain cancers.
Related Catalog
Target

DNA alkylator[1]
In Vitro Temozolomide (TZM) is a methylating agent that crosses the blood-brain barrier and is indicated for malignant gliomas and metastatic melanomas. Temozolomide is effective against tumor cells that are characterized by low levels of O6-alkylguanine DNA alkyltransferase (OGAT) and a functional mismatch repair system (MR)[1]. Determination of the IC50 for Temozolomide (TZM) in different cell lines gave values ranging from 14.1 to 234.6 μM that fell into two clearly differentiated groups: cell lines with low IC50 values (<50 μM), which include A172 (14.1±1.1 μM) and LN229 cells (14.5±1.1 μM), and those with high IC50 values (>100 μM), which include SF268 (147.2±2.1 μM) and SK-N-SH cells (234.6±2.3 μM)[2].
In Vivo Temozolomide (TZM), as a single agent, does not significantly increase mdian survival time (MST) with respect to control. Noteworthy, intracranial injection of NU1025, immediately before the administration of 100 or 200 mg/kg Temozolomide, significantly increases lifespans with respect to controls or to groups treated with Temozolomide only. When Temozolomide is fractionated, the increase in lifespan (ILS) obtained with this schedule is higher than that observed when NU1025 is combined with a single injection of Temozolomide (statistical comparison of survival curves: NU1025 intracranially+Temozolomide 100 mg/kg×2 vs NU1025+Temozolomide 200 mg/kg; P=0.023)[1].
Cell Assay The murine lymphoma cell line L5178Y of DBA/2 (H-2d/H-2d) origin is cultured in RPMI-1640 containing 10% fetal calf serum and antibiotics. Inhibition of PARP is obtained by treating cells (105 cells/mL) with 8-hydroxy-2-methylquinazolin-4[3H]-1 (NU1025), at a concentration (25 μM) that abrogates PARP activity. Cells are then exposed to Temozolomide (7.5-125 μM) and are cultured for 3 days. Cell growth is evaluated by counting viable cells in quadruplicate, and apoptosis is assessed by flow cytometry analysis of DNA content. Long-term survival is analyzed by colony-formation assay[1].
Animal Admin Mice[1] Male B6D2F1 (C57BL/6×DBA/2) mice are anesthetized with ketamine (100 mg/kg) and xylazine (5 mg/kg) in 0.9% NaCl solution (10 mL/kg intraperitoneally). L5178Y cells (104 in 0.03 mL RPMI-1640) are then injected intracranially, through the center-middle area of the frontal bone to a 2-mm depth, using a 0.1-mL glass microsyringe and a 27-gauge disposable needle. To evaluate tumor cell growth, brains are fixed in 10% phosphate-buffered formaldehyde, and histologic sections (5 μm) are cut along the axial plane, stained with hematoxylin-eosin, and analyzed by light microscopy. Temozolomide is dissolved in DMSO (40 mg/mL), diluted in saline (5 mg/mL), and administered intraperitoneally on day 2 after tumor injection at 100 mg/kg or 200 mg/kg, doses commonly used for in vivo preclinical studies. Because cytotoxicity induced by Temozolomide and PARP inhibitors can be improved by fractionated modality of treatment, in selected groups a total dose of 200 mg/kg Temozolomide is divided in 2 doses of 100 mg/kg given on days 2 and 3.
References

[1]. Tentori L, et al. Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site. Blood. 2002 Mar 15;99(6):2241-4.

[2]. Perazzoli G, et al. Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression. PLoS One. 2015 Oct 8;10(10):e0140131.

 Chemical & Physical Properties

Density 2.0±0.1 g/cm3
Boiling Point 526.6±42.0 °C at 760 mmHg
Melting Point 212°C dec.
Molecular Formula C6H6N6O2
Molecular Weight 194.151
Flash Point 272.3±27.9 °C
Exact Mass 194.055222
PSA 108.17000
LogP -1.32
Vapour Pressure 0.0±1.4 mmHg at 25°C
Index of Refraction 1.895
Storage condition 2-8°C

 Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :
NJ5927050
CHEMICAL NAME :
Imidazo(5,1-d)(1,2,3,5)tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo-
CAS REGISTRY NUMBER :
85622-93-1
LAST UPDATED :
199612
DATA ITEMS CITED :
3
MOLECULAR FORMULA :
C6-H6-N6-O2
MOLECULAR WEIGHT :
194.18

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
125 mg/kg
TOXIC EFFECTS :
Tumorigenic - active as anti-cancer agent

MUTATION DATA

TYPE OF TEST :
DNA damage
TEST SYSTEM :
Rodent - mouse Leukocyte
DOSE/DURATION :
100 umol/L
REFERENCE :
CNREA8 Cancer Research. (Public Ledger Building, Suit 816, 6th & Chestnut Sts., Philadelphia, PA 19106) V.1- 1941- Volume(issue)/page/year: 47,4884,1987

 Safety Information

Symbol GHS07 GHS08
GHS07, GHS08
Signal Word Danger
Hazard Statements H302-H315-H319-H335-H350-H360
Precautionary Statements P201-P261-P305 + P351 + P338-P308 + P313
Personal Protective Equipment Eyeshields;full-face particle respirator type N100 (US);Gloves;respirator cartridge type N100 (US);type P1 (EN143) respirator filter;type P3 (EN 143) respirator cartridges
Hazard Codes T: Toxic;Xi: Irritant;
Risk Phrases R45
Safety Phrases S24/25-S45-S36/37-S26-S53
RIDADR NONH for all modes of transport
RTECS NJ5927050
HS Code 2933990090

 Synthetic Route

 Customs

HS Code 2933990090
Summary 2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

 Articles206

More Articles
Combination of systemic chemotherapy with local stem cell delivered S-TRAIL in resected brain tumors.

Stem Cells 33(1) , 101-10, (2014)

Despite advances in standard therapies, the survival of glioblastoma multiforme (GBM) patients has not improved. Limitations to successful translation of new therapies include poor delivery of systemi...
Olanzapine inhibits proliferation, migration and anchorage-independent growth in human glioblastoma cell lines and enhances temozolomide's antiproliferative effect.

J. Neurooncol. 122(1) , 21-33, (2015)

The poor prognosis of patients with glioblastoma fuels the search for more effective therapeutic compounds. We previously hypothesised that the neuroleptic olanzapine may enhance antineoplastic effect...
A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib

Biochem. Pharmacol. 95 , 16-27, (2015)

Nitrobenzoxadiazoles exert antitumor effects against vemurafenib-resistant melanoma cells by sustained activation of different MAPK pathways.

 Synonyms

Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo-
Temodal
Temozolamide
3-Methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide
TZM
M&B 39831
TEMODAR
Temozolomide
MFCD00866492
temosolomide
Top Suppliers:I want be here

Get all suppliers and price by the below link:

Temozolomide suppliers

Price: ￥390/10mg

Reference only. check more Temozolomide price

Related Compounds: More...
Temozolomide-d3
208107-14-6
Temozolomideacid
113942-30-6
Temozolomide INT
6285-64-9
cyanotemozolomide
114601-31-9
TeMozoloMide Metabolite-MTIC
1232679-46-7
TeMozoloMide Related CoMpound A
24316-91-4
Chemsrc provides Temozolomide(CAS#:85622-93-1) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of Temozolomide are included as well.>> amp version: Temozolomide

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2024 ChemSrc All Rights Reserved